期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗联合化疗治疗弥漫大B细胞淋巴瘤疗效及不良反应分析 被引量：4

原文传递
导出
摘要 目的观察利妥昔单抗联合化疗治疗弥漫大B细胞淋巴瘤疗效及不良反应。方法选取弥漫大B细胞淋巴瘤患者84例作为研究对象,随机分为对照组和观察组,每组42例。对照组采用传统的化疗方案治疗,观察组在化疗治疗的前提下结合利妥昔单抗进行治疗,观察比较2组临床效果和不良反应。结果经2种方案治疗后,观察组患者的疗效高于对照组,且不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论利妥昔单抗联合化疗疗法可提高弥漫大B细胞淋巴瘤患者的临床治疗效果,同时降低不良反应发生率,具有较好的安全性。
作者 胡天廉
机构地区 广西容县人民医院
出处 《临床合理用药杂志》 2017年第8期54-55,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 利妥昔单抗 弥漫大B细胞淋巴瘤 化学治疗
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献35

  • 1Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin' s lympho- ma: final analysis of the prospective LNH87-2 protocol a grouped' Etude des lymphomes de 1' Aduhe study. J Clin Oneol, 2000, 18:3025-3030.
  • 2Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med, 2004, 350 : 1287-1295.
  • 3Linch DC, Yung L, Smith P, et al. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients < 65 years with poor prognosis histologically aggressive NHL. Br J Haematol, 2010, 149:237-243.
  • 4Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Grouped' Etude des Lym- phomes de 1' Adulte. J Clin Oncol, 2005, 23:4117-4126.
  • 5Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d' Etudes des Lym- phomes de 1' Adulte. Blood, 2010, 116: 2040-2045.
  • 6Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol, 2010, 28:2373-2380.
  • 7Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo pur- ging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000, 96 : 864-869.
  • 8Galimberti S, Guerrini F, Morabito F, et al. Quantitative molecu- lar evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplant, 2003, 32:57-63.
  • 9Dilhuydy MS, Lamy T, Foussard C, et al. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma : final results of a Phase II GOELAMS Study. Biol Blood Marrow Transplant, 2010, 16:672-677.
  • 10Lanini S, Molloy AC, Fine PE, et al. Risk of infection in pa- tients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med, 2011, 9:36.

共引文献23

同被引文献51

引证文献4

二级引证文献8

临床合理用药杂志
2017年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部